A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies

Trial Profile

A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Everolimus (Primary) ; Anakinra; Denosumab
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
    • 05 Mar 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2020.
    • 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top